Scienture’s Arbli added to three pediatric hospital formularies
Commack, New York - Scienture Holdings Inc. (NASDAQ: SCNX) has announced that its Arbli oral suspension, containing losartan potassium, has been added to the formularies of three prominent U.S. pediatric hospitals and medical centers as per a press release. Arbli is specifically designed for patients struggling to swallow tablets, catering to both children and older adults.
The drug is approved to manage both adult and pediatric (age 6+) hypertension. Scienture reported a rising trend in wholesale orders for Arbli, citing IQVIA data showing an annual market in the U.S. of about $219 million and 72 million prescriptions. Narasimhan Mani, Scienture's President and Co-CEO, noted the growing momentum in Arbli's commercial rollout, with increasing wholesale orders and expanding adoption across healthcare channels.
Unlike other products, Arbli is a ready-to-use 10 mg/mL oral suspension, requiring no pharmacy compounding, and comes in a 165 mL peppermint-flavored bottle that does not need refrigeration and stays potent for 24 months at room temperature. Scienture is exploring more hospital and institutional formulary placements as part of its strategy to broaden payer coverage, pharmacy availability, and distribution access.
The company currently holds two patents from the U.S. Patent and Trademark Office for Arbli, all listed in the FDA Orange Book.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
